Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2026 16:30 ET | Source: DBV Technologies S.A.

DBV Technologies intégrera l’Indice Euronext Tech Leaders

Châtillon, France, le 23 juin (22 :30 CET) 2026 DBV Technologies intégrera l’Indice Euronext Tech Leaders DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT – CUSIP...
June 23, 2026 16:05 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell...
June 23, 2026 16:01 ET | Source: Lakefront Biotherapeutics

Acquisition of Own Shares

Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT)...
June 23, 2026 16:01 ET | Source: Lakefront Biotherapeutics

Inkoop van eigen aandelen

Mechelen, België; 23 juni 2026, 22.01 CET; gereglementeerde informatie In het kader van het op 9 juni 2026 aangekondigde inkoopprogramma maakt Lakefront Biotherapeutics NV (Euronext & NASDAQ:...
June 23, 2026 14:00 ET | Source: Coherus Oncology, Inc.

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical...
June 23, 2026 13:19 ET | Source: Applied Biologics

Applied Biologics Announces Submission of Abstract of Single-Layer Amniotic Membrane Plus Standard of Care for Chronic Diabetic Foot Ulcers: An Updated Analysis of The Campx Trial to SAWC Fall 2026

Applied Biologics submits CAMPX Trial abstract to SAWC Fall 2026, showing XWRAP improved DFU closure rates to 30.9% vs. 17.5% for standard of care alone.
June 23, 2026 12:00 ET | Source: GENFIT S.A.

GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

GENFIT today announced positive Phase 1b results for GNS561 in combination therapy in patients with heavily pretreated cholangiocarcinoma
June 23, 2026 12:00 ET | Source: GENFIT S.A.

GENFIT : Données positives de Phase 1b obtenues avec GNS561 en combinaison, dans une population de patients atteints de cholangiocarcinome lourdement prétraités

Le médicament expérimental GNS561 a démontré un profil de sécurité et de tolérabilité favorable dans une étude de Phase 1b évaluant son potentiel en combinaison avec un inhibiteur de MEK (MEKi)Étude...
June 23, 2026 12:00 ET | Source: Restem

RESTEM to Present at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

MIAMI, June 23, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today...
June 23, 2026 09:25 ET | Source: Asimov

Asimov Launches Chrysalis Transposase, a Wholly-Owned Genome Integration Tool for Biotherapeutics Production

Engineered from the genomes of multiple butterfly species, Chrysalis transposase achieves high titers, stable expression, and faster cell recovery.